DYSLIPIDEMIAS

Pharmacology and Therapeutics: Principles to Practice

Volumn , Issue , 2008, Pages 303-320

  Murphy, Matthew S ^a,b   O'Brien, Timothy ^a,b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158965676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3291-5.50027-5     Document Type: Chapter

References (230)

1. D Yach, SR Leeder, J Bell, et al. (2005) Global chronic diseases. Science 307(5708), 317.
2. S Yusuf, S Hawken, S Ounpuu, et al. (2004) Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364(9438), 937-952.
3. J Costa, M Borges, C David, et al. (2006) Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332(7550), 1115-1124.
4. S Yusuf, S Reddy, S Ounpuu, et al. (2001) Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104 2746-2753.
5. T Sudhop and K von Bergmann (2002) Cholesterol absorption inhibitors for the treatment of hypercholesterolaemia. Drugs 62 2333-2347.
6. NO Davidson (1993) Apolipoprotein B mRNA editing: a key controlling element targeting fats to proper tissue. Ann Med 25 539-543.
7. M Graner, J Kahri, T Nakano, et al. (2006) Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease. Eur J Clin Invest 36 764-770.
8. A Kassai, L Illyes, HZ Mirdamadi, et al. (2007) The effect of atorvastatin therapy on lecithin: cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 40 1-5.
9. R Ross (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340 115-126.
10. M Naghavi, P Libby, E Falk, et al. (2003) From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108 1664-1672.
11. T Gordon, WP Castelli, MC Hjortland, et al. (1977) Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. The Framingham study. Ann Intern Med 87 393-397.
12. J Pekkanen, S Linn, G Heiss, et al. (1990) Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 322 1700-1707.
13. MA Austin, JE Hokanson and KL Edwards (1998) Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81(4A), 7B-12B.
14. DJ Gordon, JL Probstfield, RJ Garrison, et al. (1989) High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79 8-15.
15. Y Cui, RS Blumenthal, JA Flaws, et al. (2001) Non—high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 161 1413-1419.
16. SM Grundy (2006) Does a diagnosis of metabolic syndrome have value in clinical practice? Am J Clin Nutr 83 1248-1251.
17. SM Grundy, JI Cleeman, SR Daniels, et al. (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 2735-2752.
18. I Shai, EB Rimm, SE Hankinson, et al. (2004) Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 110 2824-2830.
19. JE Hokanson and MA Austin (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 213-219.
20. M Navab, GM Anantharamaiah, ST Reddy, et al. (2006) Mechanisms of disease: proatherogenic HDL—an evolving field. Nat Clin Pract Endocrinol Metab 2 504-511.
21. SM Grundy, JI Cleeman, CN Merz, et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 720-732.
22. PJ Barter, CM Ballantyne, R Carmena, et al. (2006) Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 247-258.
23. T Pischon, CJ Girman, FM Sacks, et al. (2005) Non—high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation 112 3375-3383.
24. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report (2002) Circulation 106 3143-3421.
25. AR Folsom, LE Chambless, CM Ballantyne, et al. (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the Atherosclerosis Risk in Communities study. Arch Intern Med 166 1368-1373.
26. RS Vasan (2006) Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113 2335-2362.
27. J Danesh, R Collins and R Peto (2000) Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 1082-1085.
28. A Deb and NM Caplice (2004) Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 27 258-264.
29. S Tsimikas, ES Brilakis, ER Miller, et al. (2005) Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 353 46-57.
30. MA Albert, J Torres, RJ Glynn, et al. (2004) Perspective on selected issues in cardiovascular disease research with a focus on black Americans. Circulation 110 e7-e12.
31. R Guerra, Z Yu, S Marcovina, et al. (2005) Lipoprotein(a) and apolipoprotein(a) isoforms: no association with coronary artery calcification in the Dallas Heart Study. Circulation 111 1471-1479.
32. CD Meyers, VS Kamanna and ML Kashyap (2004) Niacin therapy in atherosclerosis. Curr Opin Lipidol 15 659-665.
33. JD Otvos, D Collins, DS Freedman, et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113 1556-1563.
34. KH Bonaa, I Njolstad, PM Ueland, et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 1578-1588.
35. PF Jacques, J Selhub, AG Bostom, et al. (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 340 1449-1454.
36. E Lonn, S Yusuf, MJ Arnold, et al. (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 1567-1577.
37. TA Pearson, GA Mensah, RW Alexander, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107 499-511.
38. BM Scirica and DA Morrow (2006) Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113 2128-2134. discussion 2151.
39. XM Sun, ER Eden, I Tosi, et al. (2005) Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia. Hum Mol Genet 14 1161-1169.
40. RP Naoumova, GR Thompson and AK Soutar (2004) Current management of severe homozygous hypercholesterolaemias. Curr Opin Lipidol 15 413-422.
41. F Civeira (2004) Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173 55-68.
42. DW Bilheimer, JL Goldstein, SM Grundy, et al. (1984) Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 311 1658-1664.
43. D Tejedor, S Castillo, P Mozas, et al. (2005) Reliable low-density DNA array based on allele-specific probes for detection of 118 mutations causing familial hypercholesterolemia. Clin Chem 51 1137-1144.
44. MI Sirinian, F Belleudi, F Campagna, et al. (2005) Adaptor protein ARH is recruited to the plasma membrane by low density lipoprotein (LDL) binding and modulates endocytosis of the LDL/LDL receptor complex in hepatocytes. J Biol Chem 280 38416-38423.
45. RP Naoumova, C Neuwirth, P Lee, et al. (2004) Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. Atherosclerosis 174 165-172.
46. G Zuliani, M Arca, A Signore, et al. (1999) Characterization of a new form of inherited hypercholesterolemia: familial recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 19 802-809.
47. JL Goldstein, HG Schrott, WR Hazzard, et al. (1973) Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 52 1544-1568.
48. A Zambon, BG Brown, SS Deeb, et al. (2006) Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. J Intern Med 259 473-480.
49. JD Brunzell, HG Schrott, AG Motulsky, et al. (1976) Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 25 313-320.
50. CC Shoulders, EL Jones and RP Naoumova (2004) Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13(spec no 1), R149-R160.
51. GP Jarvik, JD Brunzell, MA Austin, et al. (1994) Genetic predictors of FCHL in four large pedigrees. Influence of ApoB level major locus predicted genotype and LDL subclass phenotype. Arterioscler Thromb 14 1687-1694.
52. AF Ayyobi, SH McGladdery, MJ McNeely, et al. (2003) Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 1289-1294.
53. M Junyent, R Gilabert, D Zambon, et al. (2005) The use of Achilles tendon sonography to distinguish familial hypercholesterolemia from other genetic dyslipidemias. Arterioscler Thromb Vasc Biol 25 2203-2208.
54. MD Patel and PD Thompson (2006) Phytosterols and vascular disease. Atherosclerosis 186 12-19.
55. M Reina, JD Brunzell and SS Deeb (1992) Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes. J Lipid Res 33 1823-1832.
56. SB Iskandar and KE Olive (2004) Plasmapheresis as an adjuvant therapy for hypertriglyceridemia-induced pancreatitis. Am J Med Sci 328 290-294.
57. JF Oram and JW Heinecke (2005) ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 85 1343-1372.
58. B Vanloo, F Peelman, K Deschuymere, et al. (2000) Relationship between structure and biochemical phenotype of lecithin: cholesterol acyltransferase (LCAT) mutants causing fish-eye disease. J Lipid Res 41 752-761.
59. JA Kuivenhoven, H Pritchard, J Hill, et al. (1997) The molecular pathology of lecithin: cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 38 191-205.
60. L Calabresi, L Pisciotta, A Costantin, et al. (2005) The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol 25 1972-1978.
61. GK Hovingh, BA Hutten, AG Holleboom, et al. (2005) Compromised LCAT function is associated with increased atherosclerosis. Circulation 112 879-884.
62. M Dammerman and JL Breslow (1995) Genetic basis of lipoprotein disorders. Circulation 91 505-512.
63. D Duffy and DJ Rader (2006) Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport. Circulation 113 1140-1150.
64. L Calabresi, CR Sirtori, R Paoletti, et al. (2006) Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases. Curr Atheroscler Rep 8 163-167.
65. M Navab, GM Anantharamaiah, ST Reddy, et al. (2006) Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3 540-547.
66. J Wang and RA Hegele (2000) Microsomal triglyceride transfer protein (MTP) gene mutations in Canadian subjects with abetalipoproteinemia. Hum Mutat 15 294-295.
67. RR Sankatsing, SW Fouchier, S de Haan, et al. (2005) Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol 25 1979-1984.
68. MF Linton, RV Farese Jr and SG Young (1993) Familial hypobetalipoproteinemia. J Lipid Res 34 521-541.
69. G De Backer, E Ambrosioni, K Borch-Johnsen, et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 24 1601-1610.
70. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice (2005) Heart 91(suppl 5), v1-v52.
71. JB Thompson, JJ Rivera, RS Blumenthal, et al. (2006) Primary prevention for patients with intermediate Framingham risk scores. Curr Cardiol Rep 8 261-266.
72. The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001) Executive summary. JAMA 285 2486-2497.
73. National Cholesterol Education Program (1994) Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 89 1333-1445.
74. National Cholesterol Education Program (1991) Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction: executive summary. National Heart, Lung and Blood Institute, National Institutes of Health. Arch Intern Med 151 1071-1084.
75. AH Lichtenstein, LJ Appel, M Brands, et al. (2006) Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 114 82-96.
76. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial (2002) Lancet 360(9326), 7-22.
77. J Shepherd, GJ Blauw, MB Murphy, et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360(9346), 1623-1630.
78. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) (2002) JAMA 288 2998-3007.
79. PS Sever, B Dahlof, NR Poulter, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361(9364), 1149-1158.
80. CP Cannon, E Braunwald, CH McCabe, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 1495-1504.
81. NJ Stone, S Bilek and S Rosenbaum (2005) Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 96(4A), 53E-59E.
82. A Endo, M Kuroda and Y Tsujita (1976) ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo) 29 1346-1348.
83. J Rutishauser (2006) The role of statins in clinical medicine—LDL-cholesterol lowering and beyond. Swiss Med Wkly 136(3–4), 41-49.
84. M Myerson, C Ngai, J Jones, et al. (2005) Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res 46 2735-2744.
85. MJ Chapman, M Caslake, C Packard, et al. (2003) New dimension of statin action on ApoB atherogenicity. Clin Cardiol 26(1 suppl 1), I7-I10.
86. HN Ginsberg (2006) Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia [Review]. J Clin Endocrinol Metab 91 383-392.
87. JE Edwards and RA Moore (2003) Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double blind trials. BMC Fam Pract 4 18.
88. DP Mikhailidis and AS Wierzbicki (2000) HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Curr Med Res Opin 16 139-146.
89. EJ Schaefer and BF Asztalos (2006) The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 8 41-49.
90. JW Cheng (2004) Rosuvastatin in the management of hyperlipidemia. Clin Ther 26 1368-1387.
91. PH Jones, MH Davidson, EA Stein, et al. (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 92 152-160.
92. JR Crouse 3rd, J Frohlich, L Ose, et al. (1999) Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I. Am J Cardiol 83 1476-1477. A1477.
93. TM Heinonen, E Stein, SR Weiss, et al. (1996) The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double-masked study. Clin Ther 18 853-863.
94. GG Schwartz, AG Olsson, MD Ezekowitz, et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 1711-1718.
95. M Crisby, G Nordin-Fredriksson, PK Shah, et al. (2001) Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 926-933.
96. JL Martin-Ventura, LM Blanco-Colio, A Gomez-Hernandez, et al. (2005) Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36 1796-1800.
97. P Libby and M Aikawa (2002) Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med 8 1257-1262.
98. EM Balk, J Lau, LC Goudas, et al. (2003) Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139 670-682.
99. PM Ridker, CP Cannon, D Morrow, et al. (2005) C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352 20-28.
100. JA de Lemos, MA Blazing, SD Wiviott, et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292 1307-1316.
101. A Tornio, MK Pasanen, J Laitila, et al. (2005) Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. Basic Clin Pharmacol Toxicol 97 104-108.
102. H Lennernas and G Fager (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 32 403-425.
103. MA Omar and JP Wilson (2002) FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 36 288-295.
104. PD Thompson, P Clarkson and RH Karas (2003) Statin-associated myopathy. JAMA 289 1681-1690.
105. H Iwata, K Matsuo, S Hara, et al. (2006) Use of hydroxy-methyl-glutaryl coenzyme A reductase inhibitors is associated with risk of lymphoid malignancies. Cancer Sci 97 133-138.
106. M Law and AR Rudnicka (2006) Statin safety: a systematic review. Am J Cardiol 97(8A), 52C-60C.
107. WS Smellie (2006) Testing pitfalls and summary of guidance in lipid management. BMJ 333(7558), 83-86.
108. JC LaRosa, D Hunninghake, D Bush, et al. (1990) The cholesterol facts. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 81 1721-1733.
109. J Shepherd, SM Cobbe, I Ford, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333 1301-1307.
110. RC Pasternak, SC Smith Jr, CN Bairey-Merz, et al. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40 567-572.
111. DJ Graham, JA Staffa, D Shatin, et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292 2585-2590.
112. CM Ballantyne, A Corsini, MH Davidson, et al. (2003) Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 163 553-564.
113. P Kaufmann, M Torok, A Zahno, et al. (2006) Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 63 2415-2425.
114. DG Bailey and GK Dresser (2004) Interactions between grapefruit juice and cardiovascular drugs. Am J Cardiovasc Drugs 4 281-297.
115. AV Sorokin, B Duncan, R Panetta, et al. (2006) Rhabdomyolysis associated with pomegranate juice consumption. Am J Cardiol 98 705-706.
116. KA Antons, CD Williams, SK Baker, et al. (2006) Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 119 400-409.
117. MJ Cziraky, VJ Willey, JM McKenney, et al. (2006) Statin safety: an assessment using an administrative claims database. Am J Cardiol 97(8A), 61C-68C.
118. GD Vladutiu, Z Simmons, PJ Isackson, et al. (2006) Genetic risk factors associated with lipid-lowering drug-induced myopathies. Muscle Nerve 34 153-162.
119. BA Golomb (2005) Implications of statin adverse effects in the elderly. Expert Opin Drug Saf 4 389-397.
120. G Riesco-Eizaguirre, FJ Arpa-Gutierrez, M Gutierrez, et al. (2003) [Severe polymyositis with simvastatin use]. Rev Neurol 37 934-936.
121. P Zuech, C Pauwels, C Duthoit, et al. (2005) [Pravastatin-induced dermatomyositis]. Rev Med Interne 26 897-902.
122. P Chazerain, G Hayem, S Hamza, et al. (2001) Four cases of tendinopathy in patients on statin therapy. Joint Bone Spine 68 430-433.
123. DI Chasman, D Posada, L Subrahmanyan, et al. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA 291 2821-2827.
124. LU Gerdes, C Gerdes, K Kervinen, et al. (2000) The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian Simvastatin Survival Study. Circulation 101 1366-1371.
125. JF Carlquist, JB Muhlestein, BD Horne, et al. (2003) The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J 146 1007-1014.
126. C Lahoz, R Pena, JM Mostaza, et al. (2005) The -514C/T polymorphism of the hepatic lipase gene significantly modulates the HDL-cholesterol response to statin treatment. Atherosclerosis 182 129-134.
127. C Lahoz, R Pena, JM Mostaza, et al. (2003) Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 168 289-295.
128. C Lahoz, R Pena, JM Mostaza, et al. (2005) Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment. Metabolism 54 741-747.
129. MS Sabatine, JG Seidman and CE Seidman (2006) Cardiovascular genomics. Circulation 113 e450-e455.
130. SM Boekholdt, FM Sacks, JW Jukema, et al. (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation 111 278-287.
131. SE Humphries and A Hingorani (2006) Pharmacogenetics: progress, pitfalls and clinical potential for coronary heart disease. Vascul Pharmacol 44 119-125.
132. G Schmitz and T Langmann (2006) Pharmacogenomics of cholesterol-lowering therapy. Vascul Pharmacol 44 75-89.
133. W Insull Jr (2006) Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 99 257-273.
134. RJ West and JK Lloyd (1975) The effect of cholestyramine on intestinal absorption. Gut 16 93-98.
135. H Saraux, H Offret and VG Levy (1980) [Severe amblyopia caused by vitamin A deficiency induced by prolonged cholestyramine treatment]. Bull Soc Ophtalmol Fr 80(4–5), 367-368.
136. K Vroonhof, HJ van Rijn and J van Hattum (2003) Vitamin K deficiency and bleeding after long-term use of cholestyramine. Neth J Med 61 19-21.
137. EB Melian and GL Plosker (2001) Colesevelam. Am J Cardiovasc Drugs 1 141-146. discussion 147–148.
138. MH Davidson, MA Dillon, B Gordon, et al. (1999) Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 159 1893-1900.
139. S Devaraj, B Autret and I Jialal (2006) Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia. Am J Cardiol 98 641-643.
140. HE Bays, M Davidson, MR Jones, et al. (2006) Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 97 1198-1205.
141. DL Sprecher, J Abrams, JW Allen, et al. (1994) Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 120 537-543.
142. LA Carlson and G Rosenhamer (1988) Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 223 405-418.
143. J McKenney, M Jones and S Abby (2005) Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia. Curr Med Res Opin 21 1403-1412.
144. A Armani and PP Toth (2006) Colesevelam hydrochloride in the management of dyslipidemia. Expert Rev Cardiovasc Ther 4 283-291.
145. T Kosoglou, P Statkevich, AO Johnson-Levonas, et al. (2005) Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 44 467-494.
146. RH Knopp, H Gitter, T Truitt, et al. (2003) Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 24 729-741.
147. H Gylling and TA Miettinen (2006) Drug-induced effects on cholesterol catabolism and bile acids. Curr Opin Investig Drugs 7 214-218.
148. C Gagne, D Gaudet and E Bruckert (2002) Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105 2469-2475.
149. G Salen, K von Bergmann, D Lutjohann, et al. (2004) Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation 109 966-971.
150. AM Xydakis, JR Guyton, P Chiou, et al. (2004) Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 94 795-797.
151. S Tunaru, J Kero, A Schaub, et al. (2003) PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9 352-355.
152. JR Guyton (2004) Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 5 1385-1398.
153. PL Canner, KG Berge, NK Wenger, et al. (1986) Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8 1245-1255.
154. GE Mullin, JK Greenson and MC Mitchell (1989) Fulminant hepatic failure after ingestion of sustained-release nicotinic acid. Ann Intern Med 111 253-255.
155. F Tato, GL Vega and SM Grundy (1998) Effects of crystalline nicotinic acid—induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 81 805-807.
156. DB Hunninghake, ME McGovern, M Koren, et al. (2003) A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 26 112-118.
157. BG Brown, XQ Zhao, A Chait, et al. (2001) Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345 1583-1592.
158. G Brown, JJ Albers, LD Fisher, et al. (1990) Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 1289-1298.
159. DH Blankenhorn, SA Nessim, RL Johnson, et al. (1987) Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 257 3233-3240.
160. JN Din, DE Newby and AD Flapan (2004) Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment. BMJ 328(7430), 30-35.
161. J Zhang, S Sasaki, K Amano, et al. (1999) Fish consumption and mortality from all causes, ischemic heart disease, and stroke: an ecological study. Prev Med 28 520-529.
162. F Thies, JM Garry, P Yaqoob, et al. (2003) Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial. Lancet 361(9356), 477-485.
163. D Bhatnagar and PN Durrington (2003) Omega-3 fatty acids: their role in the prevention and treatment of atherosclerosis related risk factors and complications. Int J Clin Pract 57 305-314.
164. R Marchioli, F Barzi, E Bomba, et al. (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105 1897-1903.
165. K He, Y Song, ML Daviglus, et al. (2004) Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 109 2705-2711.
166. C Wang, WS Harris, M Chung, et al. (2006) n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr 84 5-17.
167. L Hooper, RL Thompson, RA Harrison, et al. (2006) Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ 332(7544), 752-760.
168. MJ Chapman (2005) Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther 19 135-139.
169. TA Jacobson and FH Zimmerman (2006) Fibrates in combination with statins in the management of dyslipidemia. J Clin Hypertens (Greenwich) 8 35-41. quiz 42–33.
170. WJ Pan, LE Gustavson, R Achari, et al. (2000) Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40 316-323.
171. T Prueksaritanont, C Tang, Y Qiu, et al. (2002) Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 1280-1287.
172. MH Frick, O Elo, K Haapa, et al. (1987) Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 1237-1245.
173. L Tenkanen, M Manttari, PT Kovanen, et al. (2006) Gemfibrozil in the treatment of dyslipidemia: an 18-year mortality follow-up of the Helsinki Heart Study. Arch Intern Med 166 743-748.
174. HB Rubins, SJ Robins, D Collins, et al. (1999) Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341 410-418.
175. SJ Robins, HB Rubins, FH Faas, et al. (2003) Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 1513-1517.
176. DAIS Investigators (2001) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357(9260), 905-910.
177. A Keech, RJ Simes, P Barter, et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366(9500), 1849-1861.
178. MR Jones, BA Baker and P Mathew (2004) Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics. Clin Pharmacokinet 43 943-950.
179. JD Douketis, C Macie, L Thabane, et al. (2005) Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 29 1153-1167.
180. KM Gadde and DB Allison (2006) Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 114 974-984.
181. FM Sacks and M Katan (2002) Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease. Am J Med 113(suppl 9B), 13S-24S.
182. M de Lorgeril, S Renaud, N Mamelle, et al. (1994) Mediterranean alpha-linolenic acid—rich diet in secondary prevention of coronary heart disease. Lancet 343(8911), 1454-1459.
183. TT Nguyen (1999) The cholesterol-lowering action of plant stanol esters. J Nutr 129 2109-2112.
184. S Devaraj and I Jialal (2006) The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr Rev 64(7 pt 1), 348-354.
185. KG Moruisi, W Oosthuizen and AM Opperman (2006) Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis. J Am Coll Nutr 25 41-48.
186. J Plat and RP Mensink (2005) Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol 96(1A), 15D-22D.
187. SM Grundy (2005) Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. Am J Cardiol 96(1A), 47D-50D.
188. H Buchwald, JP Matts, LL Fitch, et al. (1989) Program on the Surgical Control of the Hyperlipidemias (POSCH): design and methodology. POSCH Group. J Clin Epidemiol 42 1111-1127.
189. H Buchwald, RL Varco, JP Matts, et al. (1990) Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 323 946-955.
190. H Buchwald, RL Varco, JR Boen, et al. (1998) Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 158 1253-1261.
191. H Buchwald, SE Williams, JP Matts, et al. (2002) Overall mortality in the program on the surgical control of the hyperlipidemias. J Am Coll Surg 195 327-331.
192. VL Mango and WH Frishman (2006) Physiologic, psychologic, and metabolic consequences of bariatric surgery. Cardiol Rev 14 232-237.
193. H Buchwald, Y Avidor, E Braunwald, et al. (2004) Bariatric surgery: a systematic review and meta-analysis. JAMA 292 1724-1737.
194. AI Vinik (2005) The metabolic basis of atherogenic dyslipidemia. Clin Cornerstone 7(2–3), 27-35.
195. LF Van Gaal, AM Rissanen, AJ Scheen, et al. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365(9468), 1389-1397.
196. JP Despres, A Golay and L Sjostrom (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353 2121-2134.
197. FX Pi-Sunyer, LJ Aronne, HM Heshmati, et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295 761-775.
198. R Padwal, SK Li and DC Lau (2004) Long-term pharmacotherapy for obesity and overweight. Cochrane Database. Syst Rev (3), CD004094.
199. PA Hollander, SC Elbein, IB Hirsch, et al. (1998) Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 21 1288-1294.
200. B Hutton and D Fergusson (2004) Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 80 1461-1468.
201. JS Forrester, R Makkar and PK Shah (2005) Increasing high-density lipoprotein cholesterol in dyslipidemia by cholesteryl ester transfer protein inhibition: an update for clinicians. Circulation 111 1847-1854.
202. PJ Barter, M Caulfield, M Eriksson, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 2109-2122.
203. RW Clark (2006) Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol 6 162-168.
204. M Evans, A Roberts, S Davies, et al. (2004) Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs 64 1181-1196.
205. CE Chandler, DE Wilder, JL Pettini, et al. (2003) CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res 44 1887-1901.
206. LL Rudel, RG Lee and P Parini (2005) ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 25 1112-1118.
207. C Leon, JS Hill and KM Wasan (2005) Potential role of acyl-coenzyme A: cholesterol transferase (ACAT) inhibitors as hypolipidemic and antiatherosclerosis drugs. Pharm Res 22 1578-1588.
208. W Kramer and H Glombik (2006) Bile acid reabsorption inhibitors (BARI): novel hypolipidemic drugs. Curr Med Chem 13 997-1016.
209. P Tontonoz and DJ Mangelsdorf (2003) Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 17 985-993.
210. NL Urizar, AB Liverman, DT Dodds, et al. (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296(5573), 1703-1706.
211. W Kong, J Wei, P Abidi, et al. (2004) Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10 1344-1351.
212. N Masaki, R Tatami, T Kumamoto, et al. (2005) Ten-year follow-up of familial hypercholesterolemia patients after intensive cholesterol-lowering therapy. Int Heart J 46 833-843.
213. DJ Rader (2001) Gene therapy for familial hypercholesterolemia. Nutr Metab Cardiovasc Dis 11(suppl 5), 40-44.
214. UC Broedl and DJ Rader (2005) Gene therapy for lipoprotein disorders. Expert Opin Biol Ther 5 1029-1038.
215. C Lebherz, G Gao, JP Louboutin, et al. (2004) Gene therapy with novel adeno-associated virus vectors substantially diminishes atherosclerosis in a murine model of familial hypercholesterolemia. J Gene Med 6 663-672.
216. M Grossman, SE Raper, K Kozarsky, et al. (1994) Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6(4), 335-341.
217. M Grossman, DJ Rader, DW Muller, et al. (1995) A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1(11), 1148-1154.
218. E Zsigmond, K Kobayashi, KW Tzung, et al. (1997) Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum Gene Ther 8(16), 1921-1933.
219. K Tsukamoto, R Tangirala, SH Chun, et al. (1999) Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 19 2162-2170.
220. LM Belalcazar, A Merched, B Carr, et al. (2003) Long-term stable expression of human apolipoprotein A-I mediated by helper-dependent adenovirus gene transfer inhibits atherosclerosis progression and remodels atherosclerotic plaques in a mouse model of familial hypercholesterolemia. Circulation 107 2726-2732.
221. CL Wellington, LR Brunham, S Zhou, et al. (2003) Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1. J Lipid Res 44 1470-1480.
222. A Mertens, P Verhamme, JK Bielicki, et al. (2003) Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 107 1640-1646.
223. T Ishida, S Choi, RK Kundu, et al. (2003) Endothelial lipase is a major determinant of HDL level. J Clin Invest 111 347-355.
224. J Jalkanen, P Leppanen, K Pajusola, et al. (2003) Adeno-associated virus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor reduces atherosclerotic lesion formation in LDL receptor knockout mice. Mol Ther 8 903-910.
225. Y Liu, D Li, J Chen, et al. (2006) Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 188 19-27.
226. G Bradshaw, A Gutierrez, JH Miyake, et al. (2005) Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. Proc Natl Acad Sci U S A 102 11029-11034.
227. SC Smith Jr, J Allen, SN Blair, et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 47 2130-2139.
228. RP Mason, MF Walter, CA Day, et al. (2005) Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol 96(5A), 11F-23F.
229. A Corsini, S Bellosta, R Baetta, et al. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 84 413-428.
230. P Paramsothy and R Knopp (2006) Management of dyslipidaemias. Heart 92 1529-1534.